A Phase II Randomized Trial of Lenalidomide (NSC 703813, IND 70116) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Latest Information Update: 15 Jul 2024
At a glance
- Drugs Lenalidomide (Primary)
- Indications Astrocytoma; Glioma; Neurofibromatoses
- Focus Therapeutic Use
- 09 Jan 2024 Status changed from active, no longer recruiting to completed.
- 14 Oct 2023 Planned End Date changed from 30 Mar 2019 to 30 Jun 2024.
- 13 Mar 2020 Planned primary completion date changed from 31 Mar 2020 to 30 Jun 2020.